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mir-146a and mir-155 expression 
levels in acute graft-Versus-host 
Disease incidence
Sadaf Atarod , Mohammed Mahid Ahmed , Clare Lendrem , Kim Frances Pearce ,  
Wei Cope , Jean Norden , Xiao-Nong Wang , Matthew Collin and Anne Mary Dickinson*
Haematological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment 
for numerous hematological malignancies. However, acute graft-versus-host disease 
(aGVHD) is still the major complication causing mortality. MicroRNAs (miRNAs) play a 
significant role in inflammation and have potential as prognostic and diagnostic bio-
markers. This study investigated the role of two immune-specific miRNAs (miR-146a 
and miR-155) as biomarkers for aGVHD incidence in the peripheral blood of allo-HSCT 
patients prior to disease onset. The study showed that miR-146a and its statistical inter-
action with miR-155 at day +28 were predictive of aGVHD incidence. Interestingly, the 
expression levels of miR-146a and miR-155 negatively correlated with the transcription 
factor, SPI1 (PU.1gene) mRNA expression.
Keywords: micrornas, biological markers, acute graft-versus-host disease, allogeneic hematopoietic stem cell 
transplantation, graft-versus-host disease
inTrODUcTiOn
Graft-versus-host disease (GVHD) is a serious complication of allo-HSCT. Understanding the 
molecular pathophysiology of GVHD, in particular aGVHD, may aid patient stratification for tailored 
treatments. MicroRNA (miRNA) investigations have identified biomarker signatures for numerous 
diseases such as cancer and rheumatoid arthritis and more recently for GVHD (1–4). Since miR-146a 
and miR-155 are both involved in the adaptive and the innate immune system (5, 6), we assessed 
their role in allo-HSCT. miR-146a is essential for Treg function (7). TNF receptor-associated factor 
6 (TRAF6) and interleukin-1 receptor-associated kinase 1 (IRAK1) are miR-146a targets, and their 
expressions are regulated in a negative feedback-loop via the TLR-4 (Toll-like receptor) signaling 
pathway and NFκB activation (8, 9). IFN regulatory factor 5 (IRF5) and signal transducer and activa-
tor of transcription 1 (STAT1) are also known targets of miR-146a (10). Tang et al. (10) showed that 
overexpression of miR-146a lowered STAT1 and IRF-5 at both the molecular and the protein level. 
Moreover, it has been shown in mice that miR-146a depleted Treg cells have high levels of Stat1 and 
this results in IFN-γ mediated autoimmunity (7). In a recent GVHD murine study, miR-146a was 
under-expressed in the aGVHD group and the expression correlated with disease severity, while its 
target, Traf6, was overexpressed, suggesting the involvement of NFκB activity (4).
miR-155 is required for normal B and T lymphocyte function in humans (11). miR-155 is nec-
essary for CD8+ T cell proliferation, and its deficiency can lead to the overexpression of STAT1, 
leading to down regulation of proliferation of T cells (12, 13). In a GVHD patient cohort (n = 5), 
miR-155 was overexpressed in the gut of aGVHD patients while its expression was absent in normal 
gut (1). Recently, a murine study has shown that miR-155 expression activates inflammasomes via 
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the migration of dendritic cells (14). Thus, inhibiting miR-155 
expression may reduce GVHD severity.
In addition to TRAF6, IRAK1, STAT1, and IRF5 the important 
transcription factor, SPI1 (PU.1), which functions in hematopoi-
etic differentiation (15), also regulates the expression of miR-146a 
and miR-155 (16). In a murine study, it was demonstrated that 
Spi1 regulates the expression of both miR-146a and miR-155 by 
binding to their pre-miRNA loci (17). Hence, the primary focus 
of this investigation was miR-146a and miR-155 expression levels 
because of their known functions in both the adaptive and innate 
immune system. The aims of this investigation were: (1) to assess 
whether miR-146a and miR-155 were associated with aGVHD 
incidence and severity as well as with clinical outcomes includ-
ing overall survival (OS) and relapse, (2) to establish a statistical 
model for predicting aGVHD incidence and severity using the 
miRNA expression levels and (3) to examine the correlation 
between miR-146a and miR-155 expression with their targets 
(IRAK1, TRAF6, STAT1-α, IRF5, and SPI1).
In summary, this research has shown that miR-146a and 
miR-155 are lower in patients who go on to develop aGVHD 
(grade I–III). SPI1 is regulated by both miRNAs during the early 
stages of inflammation, and there was no correlation between the 
miRNAs and their targets.
MaTerials anD MeThODs
ethics and consent
The project was approved by the Newcastle and North Tyneside I 
Research Ethics Committee (Stemdiagnostics: 07/H0906/131). All 
the investigations were conducted in accordance with the Helsinki 
Declaration. The patients gave their informed written consent for 
whole blood, serum sample collection, testing, and analyses.
Patient study cohort
The cohort consisted of 54 patients who had undergone allo-
HSCT (2010–2013) with either Human Leukocyte Antigen 
(HLA) matched siblings or matched unrelated donors (Table 1). 
There were only seven cases of “female donor-to-male recipient” 
and overall there were 21 patient deaths (events) and 33 patients 
who were alive at the end of the study (censored cases). This 
study included only patients who developed no aGvHD or who 
developed aGVHD within the first 100-days post-transplantation 
(classic aGVHD). Patients who received donor lymphocyte 
transfusions, or started immunosuppression withdrawal, before 
100  days were excluded. None of the patients had developed 
GVHD prior to day 28. Classic maximum aGVHD grade [dis-
ease onset: median = 62 days (range: 33–100)] was assessed as 
per the NIH consensus (18) [grade 0: without (n = 26), grade I: 
mild (n = 17), grade II: moderate (n = 10) and grade III: severe 
aGVHD (n =  1)]. The incidence of chronic GVHD (cGVHD) 
was significantly associated with prior aGVHD (Table 1). In the 
patient group who did not develop aGVHD (grade 0), 50% had 
died from disease relapse and 30% due to infections, while in 
patients with aGVHD grades I–III, 37% had died of relapse and 
46% due to infections. In total two patients had died of cGVHD 
and an additional two due to other complications. Whole blood 
was collected from patients 7  days before HSCT (n =  35), at 
28 days (n = 54) and at 3 months (n = 34) post-transplantation. 
At day +28, none of the patients were on steroids nor had they 
received donor lymphocyte infusion, and all patients survived 
until day 100. All patients had received alemtuzumab.
Total rna extraction from Whole Blood
Peripheral blood was collected in PAXgene Blood RNA Tubes 
(19). The samples were stored at −20°C prior to extraction. Total 
RNA was extracted using the PAXgene Blood miRNA kit (Qiagen/
BD Company) as per the manufacturer’s guidelines. Total RNA 
quality was determined using the Nanodrop 1000 (Agilent, USA).
reverse Transcription and real-Time 
Pcrs for Micrornas and for gene 
expression
For miRNA expression assays (Life Technologies, USA): 1–10 ng 
of total RNA was reverse transcribed (RT) in a 15 μl reaction using 
Taqman specific reverse transcription primers [hsa- miR-146a-5p 
(Assay ID: 000468), miR-155-5p (Assay ID: 000479), and SNORD48 
(Assay ID: 001006)] and the Taqman miRNA Reverse Transcription 
kit. The RT PCR step was performed as per the manufacturer’s 
guidelines. miRNA-specific cDNAs were used to run qPCR using 
miRNA Taqman primer-probe sets and TaqMan® Gene Expression 
Master Mix. SNORD48 was used for normalization.
For gene expression assays, total denatured RNA (5  min at 
65°C) was RT using equal volume of master mix (1:1) consisting of: 
random hexamers (Thermo Scientific, USA), dichloro-diphenyl-
trichloroethane (Invitrogen, USA), first-strand buffer (Invitrogen), 
dNTPs (Roche Diagnostics, USA), reverse transcriptase 
(Invitrogen), and Rnase inhibitor (Promega, USA). The reaction 
mix was incubated at 37°C for 2 h and 10 min at 65°C. cDNA was 
used to run qPCR for the miRNA targets [TRAF6 (Hs00371512_
g1), IRAK1 (Hs01018347_m1), STAT1-α (Hs01014003_m1), IRF5 
(Hs00158114_m1), and SPI1 (Hs02786711_m1)]. GAPDH (Assay 
ID: 4352934E) was used as the reference gene. All the qPCRs were 
run in triplicate along with no-template controls on the 7900HT 
Fast Real-Time PCR System (Life Technologies), using standard 
thermal cycling conditions. The comparative delta-delta Cq (cycle 
quantification) method was used to calculate relative fold-changes, 
and all data were log2 transformed.
Microrna Protein Target Detection
Peripheral blood was collected into vacutainer tubes coated with 
potassium Ethylenediaminetetraacetic acid (EDTA) (Becton 
Dickinson). The blood clot was allowed to retract for 4–7 h at 
4°C and then centrifuged at 500  g. Sera were then collected 
and stored at −80°C till use. Commercially available Enzyme-
Linked Immunosorbent Assay (ELISA) kits were used for the 
detection of miRNA protein targets [TRAF6 (CSB-E14078h), 
IRAK1 (CSB-E09933h), STAT1-α (CSB-E11755h), and IRF5 
(CSB-EL011820HU)]. All the steps were performed as per the 
manufacturer’s guidelines (CUSABIO, China).
statistical analyses
Analyses were performed per time-point (day −7, day +28, and 
3 months). Statistical significance level was set at p ≤ 0.05 and for 
trend tests at p ≤ 0.1.
TaBle 1 | Frequency of patient characteristics in patients with and without incidence of agVhD grades i–iii.
cohort characteristics (n = 54) no agVhD (grade 0) (%) (n = 26) Yes agVhD (grade i–iii) (%) (n = 28) Difference 
(p-value)
no. % no. %
Patient age (median years) 54.53 (19.85–67.63) 0.741
cGVHD No 11 73 4 27 0.011
Yes 8 31 18 69
Patient gender Female 12 63 7 37 0.155
Male 14 40 21 60
Donor gender Female 8 57 6 43 0.533
Male 16 44 20 56
Graft source BM 3 50 3 50 1
PBSC 23 48 25 52
Underlying disease ALL 3 43 4 57 0.128
AML 4 27 11 73
CLL 2 100 0 0
CML 1 100 0 0
MDS 9 64 5 36
MM 2 67 1 33
MPS 2 100 0 0
NHL 3 33 6 67
SAL 0 0 1 100
Regimen Myeloablative 3 27 8 73 0.179
RIC 23 53 20 47
Protocol Flu Mel 22 55 18 45 0.133
Flu Bus 3 60 2 40
Cy 1 17 5 83
FluCycloAlem 0 0 3 100
CsA prophylaxis at day +28 (ng/ml) 159 (68–333) 0.795
Alemtuzumab 30 mg 13 52 12 48 0.497
60 mg 12 43 16 57
90 mg 1 100 0 0
Relationship SIB 11 55 9 45 0.574
MUD 15 44 19 56
Patient CMV status Negative 11 46 13 54 0.791
Positive 15 50 15 50
Donor CMV status Negative 17 53 15 47 0.418
Positive 9 41 13 59
HLA Class I mistmatches None 24 47 27 53 0.604
One 2 67 1 33
HLA Class II mismatches None 17 61 11 39 0.096
One 7 41 10 59
Two 2 22 7 78
Survival status Alive 16 48 17 52 1
Dead 10 48 11 52
Relapse status No 18 47 20 53 1
Yes 8 50 8 50
Disease status at transplant CR 2 100 0 0 0.437
CR1 11 52 10 48
CR2 4 33 8 67
CR3 2 40 3 60
Unt 4 67 2 33
Fisher’s exact test was used to estimate the difference in frequencies between the two different aGVHD groups. Significant p-values are in bold and underlined (p ≤ 0.2). cGVHD, 
chronic GVHD; BM, bone marrow; PBSC, peripheral blood stem cells; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, 
chronic myeloid leukemia; HD, Hodgkin’s disease; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPS, myeloproliferative syndrome; NHL, Non-Hodgkin’s lymphoma; 
SAL, secondary acute leukemia; RIC, reduced intensity conditioning; Flu, fludarabine; Mel, melphalan; Bus, busulfan; Cy, cytrabine; Cyclo, cyclophosphamide; TBI, total body 
irradiation; CsA, cyclosporin; CMV, cytomegalovirus; CR (1–3), complete remission; Unt, untreated; SIB, sibling; MUD: matched unrelated donor.
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Acute GVHD Incidence
Primary univariate analysis of the cohort using Fisher’s exact test was 
performed to identify clinical risk factors associated with aGVHD 
incidence. Statistical significance for initial inclusion of candidate 
risk factors was set at p ≤ 0.2, as per the statistical guidelines from 
the European Society for Blood and Marrow Transplantation (20).
TaBle 2 | statistical hierarchical model fitting for mir-146a-5p and  
mir-155-5p at day +28 postallo-hscT.
Micrornas sig. Odds ratio (95% ci)
miR-155-5p 0.069 0.34 (0.10–1.09)
miR-146a-5p 0.016 0.15 (0.03–0.70)
miR-155-5p*miR-146a-5p 0.025 0.71 (0.53–0.96)
A step-wise multivariate binary logistic generalized linear model was used for the 
prediction of aGVHD incidence.
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To obtain the best model fit, and thus the most accurate 
predictions, aGVHD incidence, which is recorded using a binary 
scale (0 = no aGVHD or 1 = aGVHD grades I–III), was assessed 
using a forward step-wise, multiple binary logistic regression 
procedure (SPSS version 21.0). This uses the logit function 
to model the probability (or “odds”) of a patient having or not 
having aGVHD, given their clinical background and miRNA 
results. In this procedure, the significant clinical risk factors were 
considered as covariates, as well as the effects of miR-146a and 
miR-155 expression levels, and to give the best model fit, their 
statistical interaction was also considered (21, 22).
Survival Analyses
Univariate Kaplan-Meir and Cox regression were used to determine 
candidate clinical risk factors for time-dependent outcomes OS and 
relapse (p ≤ 0.2). Multivariate Forward-LR Cox regression analysis 
was performed to model these outcomes (SPSS version 21.0).
Correlation of miRNAs with Targets
Spearman correlation was performed to test for strength of 
association between miRNA expression levels and their targets. 
The correlation was performed separately for those who never 
developed aGVHD (grade 0) and those who went on to develop 
grade I–III aGVHD.
Kruskal–Wallis analysis of variance was performed when there 
were three or more groups in the comparison, and Dunn’s post hoc 
test was used to safeguard against false positives (GraphPad Prism 
version 5).
resUlTs
The statistical interaction between  
mir-146a and mir-155 Was significantly 
associated with agVhD incidence at Day 
+28 Post-allo-hscT
A hierarchical model was built using a forward stepwise pro-
cedure including significant clinical risk factors, miR-146a and 
miR-155 expression levels, and their interaction, separately for 
each time-point. Only day +28 data produced a significant model 
fit. The clinical risk factors initially determined to be of possible 
relevance (p ≤ 0.2) in predicting aGVHD incidence, and which 
were included in the step-wise procedure were: patient gender, 
underlying disease, HLA class II mismatches, conditioning regi-
men, and transplant protocol (Table 1). Results showed that the 
clinical factors were not significant once both miRNA expression 
levels at day +28 were included in the model. The final model that 
resulted in the best overall fit and predictive ability included a sig-
nificant statistical interaction between the two miRNAs (Table 2: 
the “main effect” of each miRNA was included to enforce model 
hierarchy; only the main effect of miR-146a was statistically 
significant). By simple graphical or tabular examination of the 
raw data, we can see that this statistical interaction represents a 
biological synergy: if both miR-146a and miR-155 were expressed 
at low levels, this was associated with a higher incidence of 
aGVHD (Figure 1; Table 3). The classification matrix illustrating 
the predictive ability of the model showed that 69% of the patients 
were accurately classified as without aGVHD (grade 0) and 75% 
as with aGVHD incidence (grades I–III).
As the clinical risk factors were not significant in the final 
model, the equation that can be used for predicting the prob-
ability of a patient having aGVHD as a function of their miR 
expression levels is:
probability (patient has aGVHD  given miRNA levels),
exp(
=
+β0 β β β ×
β β
1Log a Log Log a Log
Log146a
146 155 146 155
1
2 3
0 1
+ +
− + +
( )
[exp( β β ×2 3Log155 (Log146a Log+ 155)]  
β0  =  intercept coefficient and β1–3  =  regression coef-
ficients, Log146a  =  −log2(miR-146a expression), Log155  = 
−log2(miR-155 expression).
In this study the probability (patient has aGVHD, given 
miRNA levels)
=
0 0022
1 91 155
.
exp[ . )]Log146a 1.091Log155 0.342(Log146a Log+ + ×  
Log146a = log2 (miR-146a expression), Log155 = log2(miR-155 
expression).
In contrast, aGVHD severity (grades II–III) was not predict-
able from miRNA expression levels for this cohort, possibly 
because the majority of the patients had either none or grade I 
aGVHD (79.6%) post day +28.
mir-146a and mir-155 expression in 
Whole Blood Was not associated with 
relapse
Patient gender, transplant protocol, donor cytomegalovirus 
status, aGVHD incidence, and mismatches in HLA Class I were 
determined as significant clinical risk factors for inclusion in the 
model building. The multivariate Cox regression model showed 
that only mismatches in HLA class I was marginally predic-
tive of patient risk of relapse [p = 0.048, HR = 4.744 (95% CI: 
1.016−22.154)], and that the expression levels of both miR-146a 
and miR-155 were not significantly associated with relapse.
a Positive correlation Was Observed 
between the mir-146a Targets at the 
mrna level
The step-wise logistic regression results, discussed previously, 
indicated that miR-146a was best for predicting aGVHD 
incidence; thus, to further understand its role in GVHD, its 
established targets (TRAF6, IRAK1, STAT1-α and IRF-5) were 
TaBle 3 | summary of mirna expression at day +28 dichotomized into 
high (↑ – above median level of expression) and low (↓ – below median) 
levels with regards to grade 0 and grades i–iii agVhD showing that when 
both mirnas are under-expressed, there is a higher probability of having 
agVhD (highlighted).
Microrna expression levels gVhD grades
(number of patients)
mir-146a-5p mir-155-5p grade 0 grade i–iii
↑ ↑ 8 7
↓ ↓ 5 10
↓ ↑ 7 5
↑ ↓ 6 6
FigUre 1 | Under-expression of mir-146a-5p and mir-155-5p leads to a higher probability of agVhD incidence. The graph demonstrates the 
miR-146a-5p and miR-155-5p expression levels at day +28, dichotomized based on aGVHD incidence (0 = no GVHD and 1 = aGVHD grades I–III). The straight-line 
shows the median expression levels in this cohort (n = 54) for miR-146a-5p (−3.845) and miR-155-5p (−4.585).
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quantified at the mRNA and protein levels. In patients without 
aGVHD [grade 0 (n = 26)], there was a trend toward a negative 
correlation between miR-146a and TRAF6 mRNA expression 
(rs = −0.37, p = 0.061) only at day +28 post-HSCT. Since all the 
miRNA targets are involved in the same pathways, we assessed 
whether their levels correlated with each other at both pre- and 
post allo-HSCT time-points. A statistically significant (p ≤ 0.002) 
positive correlation was observed between all the targets in the 
entire patient cohort (Table 4).
In addition, correlation between miR-146a and its targets 
was also assessed in the aGVHD patient cohort (grades I–III). 
Measurements at day +28 showed that there was no relationship 
between miR-146a and its targets, but there was statistically 
significant (p ≤ 0.02) positive correlation observed between all 
the targets (data not shown). At 3 months post-transplantation, 
there was a significant negative correlation (rs = −0.69, p = 0.019) 
between miR-146a and IRF5 mRNA expression. At the same 
time-point, TRAF6 and IRAK1 mRNA expression positively cor-
related with each other (rs = 0.86, p = 0.001).
irF5 mrna expression Positively 
correlated with Protein levels Measured 
in Whole Blood at Day +28 in agVhD 
Patients
The target protein levels were quantified in a representative subset 
of the cohort (grade 0, n = 5; grades I–III, n = 10). Only STAT1-α 
and IRF5 proteins were detectable by ELISA. It may be that the 
TRAF6 and IRAK1 protein levels were below the sensitivity of 
the assay [detection range (picogram per milliliter), for TRAF6: 
39-2500 and IRAK1: 312-2000].
The pre-transplant STAT1-α and IRF5 protein levels neither 
correlated with their mRNA expression nor with miR-146a-5p 
expression levels (p > 0.05) (data not shown). The day +28 protein 
levels of STAT1-α and IRF5 in the aGVHD grade 0 cohort signifi-
cantly positively correlated with each other (rs = 0.90, p = 0.037). 
At 3  months post-transplantation, there was no correlation 
between miR-146a and its protein targets. In the aGVHD cohort 
(grades I–III), at Day +28, there was a trend for positive correla-
tion between miR-146a-5p and STAT1-α protein levels (rs = 0.53, 
p = 0.092). A similar correlation was observed between STAT1-α 
mRNA and its serum protein level (rs = 0.57, p = 0.068). There 
TaBle 4 | spearman correlation showed significant positive correlation between all the mrna targets in whole blood collected from allo-hscT patients 
(n = 51–54) on day +28.
spearman correlation TRAF6 IRAK1 STAT1-α IRF5 SPI1 mir-146a
IRAK1 rs 0.800
p-value 0.000
STAT1-α rs 0.770 0.580
p-value 0.000 0.000
IRF5 rs 0.680 0.700 0.650
p-value 0.000 0.000 0.000
SPI1 rs 0.480 0.320 0.540 0.390
p-value 0.000 0.024 0.000 0.005
miR-146a rs −0.160 −0.120 0.000 −0.090 −0.450
p-value 0.264 0.392 0.981 0.542 0.016
miR-155 rs −0.170 −0.110 −0.120 −0.100 −0.530 0.220
p-value 0.229 0.438 0.394 0.504 0.004 0.114
Significant negative correlation was present for both miR-146a-5p and miR-155-5p with SPI1. rs, Spearman correlation coefficient. Significant p-values are in bold and underlined  
(p ≤ 0.05).
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was also a significant positive correlation (rs = 0.71, p = 0.009) 
between IRF5 mRNA and its serum protein level. At 3 months 
post-transplantation, there was a significant negative correlation 
(rs = −0.69, p = 0.019) between miR-146a-5p and IRF5. Some 
patients at 3 months were receiving steroids so this result must 
be interpreted with caution.
mir-155 and mir-146a expression 
correlated with the Transcription Factor, 
sPi1
In the aGVHD patient cohort (grades I–III) only, miR-155-5p 
expression was significantly negatively correlated with its target 
SPI1 in whole blood samples at day +28 (Figure 2A). In the same 
cohort, there was a significant negative correlation between miR-
146a-5p and SPI1 (Figure 2B).
DiscUssiOn
miR-146a and miR-155 have been shown to be indispensable in 
regulating immune-related pathways (6, 7, 23, 24). It is known in 
HSCT that miR-155-5p is overexpressed when target organ dam-
age has already occurred in the patient (1). It is also known that 
graft-versus-tumor effect is required to prevent disease relapse 
(25). Thus, tailoring treatments to maintain a balance between 
GVHD and graft-versus-tumor effect are important post-HSCT.
This study aimed at assessing whether the expression of the 
two miRNAs could be used to predict aGVHD prior to disease 
onset. This knowledge could make clinical interventions possible 
prior to disease onset and, therefore, prevent the complications 
associated with aGVHD. Understanding the miRNA regula-
tion involved in the pathophysiology of aGVHD could also be 
reflective of the GVH reaction and in particular the essential 
graft-versus-tumor effect, directing new therapies for improved 
HSCT disease-outcome.
The data models used in this study looked at both the main 
effects and the statistical interaction between miR-146a and 
miR-155 in predicting aGVHD incidence. In many biological 
investigations, in particular in the field of allo-HSCT, statistical 
interactions are often overlooked even though they are one of 
the keys to better fitting models (and thus better predictions) 
and to the better understanding of biological relationships. This 
investigation is one of the few studies where this method has been 
utilized for aGVHD incidence prediction.
The statistical interaction of miR-146a and miR-155 expres-
sion levels at day +28 post-transplant was significant in predicting 
aGVHD incidence, and investigation of the data revealed the con-
ditional regulation mechanism wherein when both miRNAs were 
expressed at lower levels, there was a higher incidence of aGVHD. 
The statistical interaction observed is in support of the differential 
“check-point” mechanism shown by Schulte et  al. (26). Using 
various immune system stimulators such as lipopolysaccharides 
that trigger the expression of miR-146a (8), the authors showed 
that miR-146a was upregulated first, thus initiating the inflam-
matory response. miR-155 expression was only altered when 
miR-146a levels of inflammatory tolerance had been surpassed 
(26). This may explain why higher miR-155 expression levels have 
been observed in both the serum and gut of patients at the time 
of aGVHD onset, which is the effector phase of the GVHD cycle 
(1, 27, 28). Our results support the very recent aGVHD study in 
the mouse that showed miR-146a expression levels were lower in 
severe aGVHD cases (4). This may suggest that overexpression 
of miR-146a prevents an inflammatory response and may have a 
protective role in innate immunity (23).
miR-146a expression affects the expression of TRAF6 and 
IRAK1 at the protein level rather than at the mRNA-level (29). 
But in this study using ELISAs, the protein level of IRAK1 and 
TRAF6 were undetectable in the sera of allo-HSCT patients. IRF5 
and STAT1-α proteins were detected in the allo-HSCT patients, 
but they did not correlate with miR-146a expression levels. IRF5 
mRNA expression positively correlated with its protein levels at 
day +28 in patients who went on to develop aGVHD but not in 
patients who did not develop aGVHD. Not surprisingly, a positive 
correlation was present among miR-146a-5p targets at the mRNA 
level at both pre- and post-allo-HSCT time-points. It is at the aug-
mented inflammatory stage that the miRNA expression reaches a 
level that impacts the expression levels of their targets. This may 
be the reason why no correlation was seen between miR-146a-5p 
FigUre 2 | mir-155-5p and mir-146a-5p expression directly correlated with sPi1 mrna levels. There was a significant negative correlation for both  
(a) miR-155-5p and (B) miR-146a-5p expression. The correlation was only significant in aGVHD patients with grades I–III (n = 27). The x-axis shows the miRNA 
expression levels and the y-axis the SPI1 mRNA levels. Spearman correlation was used to test for correlation. Spearman rho: rs. Significance level was set at 
p ≤ 0.05.
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and its targets pre-aGVHD onset, while the same miRNA has 
been shown to regulate Traf6 expression at aGVHD onset (4).
Mice deficient in miR-146a develop autoimmune disorders 
and die prematurely (29). Low miR-146a expression could result 
in an inflammatory phenotype and impact survival (30). This may 
suggest that patients with lower miR-146a-5p expression would 
have more graft-versus tumor effect due to exacerbated GVH 
reaction, but this could lead to fatal GVHD. When the statisti-
cally significant clinical risk factors were included in the study, 
results showed that only HLA class I mismatches were associated 
with risk of death (data not shown). This finding may suggest that 
miR-146a expression was not associated with OS when clinical 
risk factors were included in the analysis. However, there were 
only three patient-donor pairs with HLA class I mismatch and 
thus this finding is preliminary and must be considered with 
caution.
The master transcription factor SPI1 (31) controls miR-155 
expression (17). Both miRNAs are predicted to target SPI1 
according to microrna.org (32). SPI1 controls the expression 
of both miRNAs in HSCs (17). Spi1 binds to pre-miR-146a 
locus permanently to regulate its expression and to miR-155 
locus only during hematopoietic stem cell differentiation 
(17). Our results may suggest that during GVH reaction both 
miRNAs are triggered by chemokines and cytokines, which 
lead to their regulation of SPI1 rather than their activation by 
it (17, 33).
FigUre 3 | mir-146a-5p and mir-155-5p mechanism of action under normal conditions and early stages of inflammation (2, 9, 34). During the early 
stages of inflammation in GVHD, the TLR and Janus Kinase (JAK)-STAT1 pathway are activated by LPS and IFN-γ, respectively. Under such conditions, miR-146a-
5p and miR-155-5p have reduced expression levels. This results in minor alterations of the mRNA target levels and may therefore represent subclinical early 
inflammatory GVHD.
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